The association of IL7R expression after 3 doses of tebentafusp (but not prior to initiation of tebentafusp) with tumor reduction and OS suggests that recently recruited naive cells are key mediators of the anti-tumor activity of tebentafusp. This evidence concerns the gene IL7R and neoplasm.